Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1160P is a genomic locus annotated as a pseudogene derived from U6 small nuclear RNA genes. U6 small nuclear RNA (snRNA) is normally a critical non-coding RNA component of the spliceosome, the ribonucleoprotein complex responsible for removing introns from pre-mRNA during RNA splicing[1][2]. In contrast, RNU6-1160P does not encode a functional U6 snRNA due to mutations or sequence interruptions acquired during evolution, as is typical for pseudogenes[3][4]. It shares sequence similarity with functional U6 snRNA genes but is not involved in pre-mRNA splicing and does not form part of the spliceosome machinery. Pseudogenes like RNU6-1160P are common in the human genome, especially for highly conserved RNA families such as U6, but usually lack functional products or regulatory roles, unless otherwise experimentally demonstrated[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1160, pseudogene (RNU6-1160P).